SCHEMBL9924077

SCHEMBL9924077

CCOC(=O)NC1CCC(N/C(=N\C(=O)c2ccccc2)Nc2cc(F)cc(Cl)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.38
DRD2 P14416 1/20 0.38
UBE2M P61081 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38
CHRM3 P20309 3/20 0.37
LMNA P02545 3/20 0.36
ADORA3 P0DMS8 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
EPHX2 P34913 2/20 0.35
CRHR1 P34998 1/20 0.35
ADORA2B P29275 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD11B1 P28845 1/20 0.35
SLC6A9 P48067 1/20 0.34
SLC6A5 Q9Y345 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924087 0.94 HSD11B1 (0.39) GRM4LMNAADORA3NPSR1ALDH1A1
SCHEMBL9924255 0.93 GRM4 (0.36) GRM4DRD2CHRM3ALDH1A1EPHX2
SCHEMBL9924256 0.92 NPC1 (0.36) GRM4DRD2CHRM3LMNAEPHX2
SCHEMBL9924070 0.91 GRM4 (0.40) GRM4UBE2MDCUN1D1CHRM3ALDH1A1
SCHEMBL9924329 0.90 SLC6A9 (0.40) LMNAADORA3ALDH1A1EPHX2SMN1; SMN2
SCHEMBL17206702 0.90 CHRM1 (0.38) GRM4DRD2ALDH1A1EPHX2KMT2A
SCHEMBL9924228 0.90 CHRM1 (0.38) GRM4DRD2ALDH1A1EPHX2KMT2A
SCHEMBL9924259 0.90 CHRM1 (0.38) GRM4DRD2ALDH1A1EPHX2KMT2A
SCHEMBL9924331 0.90 NPC1 (0.40) LMNAALDH1A1EPHX2HTTSMN1; SMN2
SCHEMBL9924084 0.89 GRM4 (0.35) GRM4DRD2CHRM3LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed